Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T320 in Advanced Solid Tumors
NCT07434609Phase 1Not yet recruiting
- Sponsor
- Nanolattix
- Start
- Dec 2027
- Primary completion
- Dec 2029
- Modality
- Antibody-Drug Conjugates (ADCs)
01
Overview
Phase 1, open-label trial of T320 in solid tumor (advanced stage), sponsored by Nanolattix. Primary endpoints: Dose-limiting toxicity at 28 days, Adverse event and 5 more. Planned start Dec 2027; status: not yet recruiting.
02
Drugs
T320
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07434609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07434609.